
Conference Coverage
Latest Content

Shorts






Podcasts
Videos
All News

In October 2025, the FDA granted approval to multiple new cancer therapies and supportive care options, covering treatments across the oncologic landscape.

In honor of Pancreatic Cancer Awareness Month, we spoke with Dr. Rosario Ligresti about rising rates of the disease in younger adults and more.

I share how walking has helped me through lymphoma, knee surgeries and treatments, and why staying active keeps me physically, mentally and spiritually strong.

Stoboclo and Osenvelt is now interchangeable with brand-name drugs, per the FDA, letting pharmacists substitute them while ensuring safety and efficacy.

Dr. Dima El-Sharkawi discusses how hairy cell leukemia typically presents in patients and the challenges clinicians face in identifying the disease early.

Choosing treatment for stage 2 prostate cancer? Get the facts on surgery vs radiation and learn to manage possible side effects like erectile dysfunction.

Tamron Little was diagnosed with peritoneal mesothelioma after childbirth and now, 18 years later, she says survivorship is lifelong.

Participating in the SUNRiSE-1 trial taught Bill the value of education, teamwork, and persistence for patients with bladder cancer.

For Silvia Davis, a breast cancer diagnosis at the age of 36 led to a fertility preservation journey that resulted in her son, John.

Cancer has taught me to be vigilant, but also to be grateful — for modern science, for watchdog organizations, for the ability to access information instantly.

Dr. Anjana Pillai says treatment depends on stage and health, with surgery, transplant, local therapy or systemic drugs to help people live longer.

An expert discusses why up to 60% of new trial sites close in year one and what this means for patient access and research supply.

It wasn’t that I never expected a breast cancer diagnosis, it was that I had never even considered a breast cancer diagnosis.

Dr. Vinayak Venkataraman recently sat down with CURE to discuss the evolving treatment landscape for gastrointestinal stromal tumors.

The U.S. FDA has granted orphan drug designation to DPTX3186, an investigational therapy being developed for gastric cancer treatment.


























